Skin and Surface Treatment Applicator from Xoft

April 2009
Imaging Economics;Apr2009, Vol. 22 Issue 3, p40
Trade Publication
The article reports on the approval of the U.S. Food and Drug Administration (FDA) of a skin and surface treatment applicator of Xoft Inc. Accordingly, the FDA's approval entails that the applicator can be used for external and internal surface of the body for radiation therapy. Further, the applicator is for delivery of surface brachytherapy such as Intraoperative Radiation Therapy.


Related Articles

  • Xoft looks to expand Axxent radiation treatment system.  // Medical Device Daily;3/18/2008, Vol. 12 Issue 53, p10 

    The article reports on the expanded U.S. Food and Administration (FDA) clearance received by Xoft for its Axxent Electronic Brachytherapy system. It is noted that Axxent serves as a platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded...

  • FDA to review devices marketed prior to 1976.  // Biomedical Business & Technology;May2009, Vol. 32 Issue 5, p30 

    The article focuses on the plan of the U.S. Food and Drug Administration (FDA) to review 25 types of medical devices marketed before 1976. Manufacturers of the devices are required to submit safety and effectiveness information to the FDA to evaluate the risk level of each device type. The plan...

  • AdvaMed, analysts, react to FDA's new 510(k) plan. PEDERSEN, AMANDA // Medical Device Daily;1/21/2011, Vol. 15 Issue 14, p1 

    The article considers the response of the Advanced Medical Technology Association (AdvaMed) to the revised 510(k) plan introduced by the U.S. Food and Drug Administration (FDA). During a conference call on January 20, 2011, David Nexton, senior executive vice president of policy at AdvaMed,...

  • Neurowave's Reletex provides non-invasive nausea treatment. FORD, OMAR // Medical Device Daily;10/21/2010, Vol. 14 Issue 205, p1 

    The article highlights the effectiveness of the transdermal neuromodulation device Reletex from Neurowave Medical Technologies in relieving nausea when used as an adjunct to anti-emetics. It is said that Reletex, which has been cleared by the U.S. Food and Drug Administration (FDA), could...

  • Study finds FDA hurdles hindering U.S. innovation. FORD, OMAR // Medical Device Daily;11/19/2010, Vol. 14 Issue 226, p1 

    The article reports on the findings of a study which revealed that the regulatory process at the U.S. Food and Drug Administration (FDA) hampers medical technology innovation in the U.S. The study was conducted by Stanford University and led by Josh Makower. The researchers found that the cost...

  • MED-TECH. Gee, David // MinnesotaBusiness;May2010, Vol. 20 Issue 1, p33 

    The article presents commentaries of executives in the medical technology industry. The investment of Dave Stassen, managing director of Split Rock Parnters, in Disc Dynamics has alarmed him as the U.S. Food and Drug Administration (FDA) did not approve its use. President and chief executive...

  • CTT wins FDA approval for pain therapy device.  // PharmaWatch: CNS;Apr2009, Vol. 8 Issue 4, p13 

    The article reports on the announcement of Competitive Technologies Inc. (CTT) concerning the 510k authorization letter of the U.S. Food and Drug Authority (FDA) which allows U.S. sales of the pain therapy medical device of the company. It states the approval of the FDA could expand CTT's sales...

  • WASHINGTON NEWS.  // Medical Technology & Devices Week;11/10/2008, Vol. 6 Issue 45, p1 

    The article focuses on the announcement made by the U.S. Food and Drug Administration (FDA) on October 1, 2008 regarding the class I recall of the vibrational integrated bio-photonic energizer multi-frequency field generator, or Vibe. The FDA disclosed that the device from VIBE Technologies...

  • Expert predicts Congress to put industry in crosshairs.  // Medical Technology & Devices Week;11/10/2008, Vol. 6 Issue 45, p5 

    The article discusses the predicted shift in congressional oversight of medical product safety from the U.S. Food and Drug Administration to industry. John Manthei, global co-chair of Latham & Watkins, explains that the 11th Congress will be focused on safety in the manufacturing and usage of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics